Clinical and economic impact of Ventricular Assist Device infections: a real-world claims analysis.
B
B2
B21
C
C1
C13
VAD
cost
infections
mortality
Journal
Journal of medical economics
ISSN: 1941-837X
Titre abrégé: J Med Econ
Pays: England
ID NLM: 9892255
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
medline:
12
12
2023
pubmed:
12
12
2023
entrez:
12
12
2023
Statut:
aheadofprint
Résumé
VAD therapy has revolutionized the treatment of end-stage heart failure, but infections remain an important complication. The objective of this study was to characterize the clinical and economic impacts of VAD-specific infections. A retrospective analysis of a United States claims database identified members 18 years with a claim for a VAD implant procedure, at least 6 months of pre-implant baseline data, and 12 months of follow-up between June 1, 2016 and December 31, 2019. Cumulative incidence of infection was calculated. Infection and non-infection cohorts were compared regarding mortality, healthcare utilization, and total cost. Regression models were used to identify risk factors associated with infections and mortality. A total of 2,259 patients with a VAD implant were included, with 369 experiencing infection (12-month cumulative incidence 16.1%). Patients with infection were 2.1 times more likely to die ( VAD infections were associated with higher mortality, more healthcare utilization, and higher total cost. Strategies to minimize VAD-specific infections could lead to improved clinical and economic outcomes.
Sections du résumé
BACKGROUND
UNASSIGNED
VAD therapy has revolutionized the treatment of end-stage heart failure, but infections remain an important complication. The objective of this study was to characterize the clinical and economic impacts of VAD-specific infections.
METHODS
UNASSIGNED
A retrospective analysis of a United States claims database identified members 18 years with a claim for a VAD implant procedure, at least 6 months of pre-implant baseline data, and 12 months of follow-up between June 1, 2016 and December 31, 2019. Cumulative incidence of infection was calculated. Infection and non-infection cohorts were compared regarding mortality, healthcare utilization, and total cost. Regression models were used to identify risk factors associated with infections and mortality.
RESULTS
UNASSIGNED
A total of 2,259 patients with a VAD implant were included, with 369 experiencing infection (12-month cumulative incidence 16.1%). Patients with infection were 2.1 times more likely to die (
CONCLUSIONS
UNASSIGNED
VAD infections were associated with higher mortality, more healthcare utilization, and higher total cost. Strategies to minimize VAD-specific infections could lead to improved clinical and economic outcomes.
Identifiants
pubmed: 38084737
doi: 10.1080/13696998.2023.2292912
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM